In one of the initial attempts to profile circulating immune cells in early-stage NSCLC patients treated with neoadjuvant chemotherapy and ipilimumab [19], although chemotherapy had little effect on circulating immune cells, ipilimumab activated both CD4+ and CD8+ lymphocytes. The gene discussed is CD8A; the disease is non-small cell lung carcinoma.